Neurofibromatosis type 2 (NF2) patients develop multiple nervous system tumours including bilateral vestibular schwannomas (VS). The tumours and their treatment are associated with deafness, neurological disability and mortality. The UK nationally-commissioned specialty NF2 service introduced bevacizumab (BEV) for rapidly growing schwannomas in 2010.Patients treated with BEV underwent serial prospective MRI of their target tumour, regular audiology, clinical and NFTI-QOL quality of life assessments and recording of CTCAE4.0 adverse events. Annual VS surgical rates were reviewed. Volumetric tumour measurements were classified according to REiNS criteria. Spinal ependymoma frequency was assessed and retrospective review of behaviour during...
The objective of this study was to review the experience of the Neurotology and Skull Base Surgery U...
Abstract Neurofibromatosis type 2 (NF2) is a tumour-prone disorder characterised by the development ...
Bevacizumab is considered an established part of the treatment strategies available for schwannomas ...
Background: NF2 patients develop multiple nervous system tumors including bilateral vestibular schwa...
Objective: Early studies suggest that bevacizumab treatment can result in tumor shrinkage and hearin...
Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some ne...
Neurofibromatosis type 2 (NF2) is an autoso-mal dominant syndrome with a prevalence of approximately...
Background Profound hearing loss is a serious complication of neurofibromatosis type 2, a genetic co...
Patients with bilateral vestibular schwannomas associated with neurofibromatosis type 2 (NF2) experi...
Neurofibromatosis type 2 is characterized by bilateral vestibular schwannomas, which are benign tumo...
A patient with neurofibromatosis type 2 (bilateral vestibular schwannomas) was treated with bevacizu...
Neurofibromatosis type 2 (NF2) is an autosomal dominant condition caused by pathogenic variants in t...
Neurofibromatosis type 2 (NF2) is an autosomal dominant inherited diseases. NF2 patients suffer a hi...
Objective: To determine the rate of growth in vestibular schwannomas and the rate of hearing decline...
Background Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome associated with vestibular...
The objective of this study was to review the experience of the Neurotology and Skull Base Surgery U...
Abstract Neurofibromatosis type 2 (NF2) is a tumour-prone disorder characterised by the development ...
Bevacizumab is considered an established part of the treatment strategies available for schwannomas ...
Background: NF2 patients develop multiple nervous system tumors including bilateral vestibular schwa...
Objective: Early studies suggest that bevacizumab treatment can result in tumor shrinkage and hearin...
Bevacizumab treatment can result in tumor shrinkage of progressive vestibular schwannomas in some ne...
Neurofibromatosis type 2 (NF2) is an autoso-mal dominant syndrome with a prevalence of approximately...
Background Profound hearing loss is a serious complication of neurofibromatosis type 2, a genetic co...
Patients with bilateral vestibular schwannomas associated with neurofibromatosis type 2 (NF2) experi...
Neurofibromatosis type 2 is characterized by bilateral vestibular schwannomas, which are benign tumo...
A patient with neurofibromatosis type 2 (bilateral vestibular schwannomas) was treated with bevacizu...
Neurofibromatosis type 2 (NF2) is an autosomal dominant condition caused by pathogenic variants in t...
Neurofibromatosis type 2 (NF2) is an autosomal dominant inherited diseases. NF2 patients suffer a hi...
Objective: To determine the rate of growth in vestibular schwannomas and the rate of hearing decline...
Background Neurofibromatosis type 2 (NF2) is a tumor suppressor syndrome associated with vestibular...
The objective of this study was to review the experience of the Neurotology and Skull Base Surgery U...
Abstract Neurofibromatosis type 2 (NF2) is a tumour-prone disorder characterised by the development ...
Bevacizumab is considered an established part of the treatment strategies available for schwannomas ...